8-K: CV Sciences to Acquire Extract Labs in Strategic Move to Expand Cannabinoid Product Portfolio

CV Sciences, Inc. has entered into a definitive agreement to acquire Extract Labs, a leading manufacturer of cannabinoid products, for a combination of cash and stock, with potential earnout payments based on future revenue performance.

Summary

• CV Sciences, Inc. has agreed to acquire Extract Labs, a manufacturer and distributor of cannabinoid products, in a deal that includes a cash payment of $400,000, less certain adjustments, and $1,000,000 in CV Sciences stock.
• The deal also includes potential earnout payments of up to $600,000 in CV Sciences stock, contingent on Extract Labs achieving specific revenue targets over the two years following the acquisition.
• The earnout payments are structured in tiers, with $300,000 payable if Extract Labs achieves $4,600,000 in net revenue in a 12-month period, and decreasing amounts for lower revenue targets down to $0 for revenue below $3,500,000.
• The acquisition is expected to close in the first quarter of 2025, subject to customary closing conditions.
• Extract Labs is a profitable business with operational flexibility, including low minimum order quantity production runs, and is GMP-certified and FDA-registered.
• CV Sciences plans to in-source the production of some of its key products using Extract Labs' manufacturing capabilities, which is expected to lead to cost savings and greater control over the supply chain.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook with the acquisition expected to bring revenue growth and cost savings. However, there are risks associated with the integration and achievement of earnout targets, which temper the overall sentiment.

Positives

• The acquisition of Extract Labs is expected to increase CV Sciences' revenue and customer base.
• In-sourcing production is expected to lead to meaningful cost savings.
• The acquisition will provide CV Sciences with greater control over its supply chain.
• Extract Labs' operational flexibility allows for efficient use of capital and faster new product development.
• Extract Labs is a profitable business, which should positively impact CV Sciences' financials.

Negatives

• The closing payment is subject to adjustments based on Extract Labs' net working capital and assumed indebtedness.
• The earnout payments are contingent on Extract Labs achieving specific revenue targets, which may not be met.
• The acquisition is subject to customary closing conditions, which could delay or prevent the deal from closing.
• There is a risk that the expected synergies and cost savings may not be fully realized.

Risks

• The acquisition is subject to customary closing conditions, which could delay or prevent the deal from closing.
• The earnout payments are contingent on Extract Labs achieving specific revenue targets, which may not be met.
• There is a risk that the expected synergies and cost savings may not be fully realized.
• The integration of Extract Labs into CV Sciences may present operational challenges.
• The company is subject to risks and uncertainties that may cause actual results to differ from forward-looking statements.

Future Outlook

The acquisition is expected to increase CV Sciences' revenue and customer base, allow for in-sourcing of production, and drive long-term growth and shareholder value. The company plans to leverage Extract Labs' existing capacity and manufacturing capabilities to achieve these goals.

Management Comments

• Joseph Dowling, Chief Executive Officer of CV Sciences, stated that Extract Labs is a stand-alone profitable business and the plan is to increase its existing revenue base.
• Dowling also mentioned that they are planning to in-source the manufacturing of select +PlusCBD branded products, providing an opportunity for meaningful cost savings.

Industry Context

This acquisition reflects a trend in the cannabis and wellness industry where companies are consolidating to gain market share, expand product offerings, and achieve operational efficiencies. The move allows CV Sciences to strengthen its position in the cannabinoid market by adding a manufacturing capability and a broader range of products.

Comparison to Industry Standards

• The acquisition of Extract Labs by CV Sciences is similar to other strategic acquisitions in the cannabis and wellness industry, where companies seek to vertically integrate and expand their product portfolios.
• The earnout structure based on revenue targets is a common practice in acquisitions, aligning the interests of the buyer and seller.
• The focus on in-sourcing production is a strategy used by many companies to reduce costs and improve supply chain control, similar to moves by other companies in the sector.
• The valuation of the acquisition, with a mix of cash and stock, is consistent with industry norms for similar transactions.

Related Party Transactions

• Extract Labs leases a building from 1399 Horizon LLC, which is wholly-owned by Craig Henderson, a seller in the acquisition.
• Extract Labs is the guarantor of approximately $4 million of indebtedness of Horizon that is secured by a deed of trust on the Building.
• At the closing of the Acquisition, Extract Labs will enter into a new 3-year lease with Horizon.
• Following the closing of the Acquisition, Henderson and Horizon will jointly and severally indemnify Extract Labs against liability under its guarantee of the Loan.

Stakeholder Impact

• Shareholders may benefit from increased revenue and potential cost savings.
• Employees of both CV Sciences and Extract Labs may experience changes due to the integration.
• Customers may see an expanded product offering and potentially lower prices.
• Suppliers may see changes in demand and procurement processes.
• Creditors may be impacted by the changes in the company's financial structure.

Next Steps

• The acquisition is expected to close in the first quarter of 2025.
• CV Sciences will integrate Extract Labs into its operations.
• CV Sciences will begin in-sourcing production of select products.
• The company will monitor Extract Labs' revenue to determine earnout payments.

Key Dates

Keywords

acquisition, cannabinoid, hemp, extracts, manufacturing, revenue, wellness, CV Sciences, Extract Labs, merger